Abstract
Persistent depressive disorder is a form of depression that lasts for years. Reviews of research find that talking therapies, antidepressant medicines and the two combined all have some evidence of benefit, and several reviews favour the combination. Continuing treatment after improvement may lower the chance of relapse, although that evidence is limited. Childhood maltreatment is linked with a longer course and a weaker response to treatment. Many questions are still uncertain, because the trials are few, often small and rarely long.
Keywords: persistent depressive disorder, dysthymia, chronic depression, psychotherapy, antidepressants
Get Help Now
Anyone who is thinking about suicide or self-harm, or who feels unable to cope, should contact a crisis line straight away. People in immediate danger should call their local emergency number.
- United States: the 988 Suicide & Crisis Lifeline takes calls and texts at 988 (988lifeline.org). - United Kingdom: Samaritans can be called free on 116 123 (samaritans.org). - Canada: the Suicide Crisis Helpline takes calls and texts at 9-8-8 (988.ca). - Australia: Lifeline can be called on 13 11 14 (lifeline.org.au).
This guide describes what published clinical guidelines and research reviews say about treating persistent depressive disorder. It is not a substitute for advice from a doctor or other health professional who knows a person's situation.
How Treatment Is Chosen
Persistent depressive disorder is depression that lasts a long time (Schramm et al., 2020). The term covers several long-lasting forms, including dysthymia and chronic major depression (Schramm et al., 2020). One review describes it as often more disabling than depression that comes in episodes (Schramm et al., 2020). Chronic depression also tends to respond less well to standard forms of talking therapy than episodic depression (Jobst et al., 2016).
This page covers persistent depressive disorder; a general overview of depression treatment covers depression more broadly. In England, the National Institute for Health and Care Excellence (NICE) lists cognitive behavioural therapy (CBT), selective serotonin reuptake inhibitors (SSRIs, a common class of antidepressant), SNRIs, tricyclic antidepressants (TCAs, which NICE warns are dangerous in overdose, though it rates lofepramine as the safest of them), or CBT combined with an SSRI or a TCA as options for adults whose long-lasting symptoms seriously affect their daily and social life and who have had no earlier treatment for depression (National Institute for Health and Care Excellence, 2022). For people likely to benefit from extra social or vocational support, NICE suggests considering befriending alongside existing antidepressant medicine or psychological therapy, or a rehabilitation programme when depression has led to loss of work or withdrawal from social activities over the longer term, and it describes the choice of treatment as a shared decision based on the person's clinical needs and preferences (National Institute for Health and Care Excellence, 2022). A guidance paper based on a systematic search and expert consensus recommends combined talking therapy and medicine as a first-line option for chronic depression (Jobst et al., 2016). Its authors add that it is unclear which patients benefit most (Jobst et al., 2016). Anyone weighing these options can discuss them with a doctor.
Talking Therapies
Psychotherapy means treatment by talking with a trained therapist. A review of 16 randomized trials in people with chronic depression or dysthymia found that it helped more than control conditions, but the effect was small (Cuijpers et al., 2010). Benefit seemed greater when therapy ran to 18 sessions or more (Cuijpers et al., 2010). In dysthymia only, medicine did better than talking therapy, and the authors judged therapy probably less effective than SSRIs (Cuijpers et al., 2010).
A broader review of 28 studies with 3,381 people found no clear difference between talking therapy and medicine at the end of treatment (Imel et al., 2008). Medicine had a small advantage in dysthymia, while across all the types of depression in the review talking therapy did better at later follow-up, which suggests it may offer some protection (Imel et al., 2008). Only a minority of its studies reported follow-up, and few included dysthymia (Imel et al., 2008).
The Cognitive Behavioral Analysis System of Psychotherapy (CBASP) is a talking therapy tested in chronic depression (Negt et al., 2016). A review of 6 trials with 1,510 chronically depressed patients found that CBASP beat comparison treatments, though the combined effect was small (Negt et al., 2016). It did about as well as antidepressants, and CBASP plus an antidepressant did better than the antidepressant alone (Negt et al., 2016). That review had few studies, and only one followed people up over time (Negt et al., 2016). An analysis of 3 studies with 1,036 participants also found CBASP and medicine about equal on average, with the combination better than either alone in both benefit and acceptability, although for certain groups of patients either treatment alone was a reasonable option (Furukawa et al., 2018).
Medicines
A placebo is a dummy pill with no active medicine. In a review of 194 trials, 17 of them in dysthymia, antidepressants worked better than placebo for dysthymia (Levkovitz et al., 2011). The placebo response was lower in dysthymia than in major depression, about 30% compared with about 38% (Levkovitz et al., 2011). The authors called for longer-term studies (Levkovitz et al., 2011).
A review of 20 studies, mostly in dysthymia, found that SSRIs and tricyclic antidepressants (TCAs) both beat placebo, with no clear difference in benefit between them (von Wolff et al., 2013). Fewer people dropped out on SSRIs than on TCAs, so SSRIs were better accepted (von Wolff et al., 2013).
A network review of 34 trials with 4,769 adults compared side effects (Meister et al., 2016). TCAs, along with trazodone (tested in one study), had the highest rates of stopping because of side effects, and the odds of stopping for that reason were about twice as high on TCAs as on SSRIs (Meister et al., 2016). SSRIs caused no clearly greater rate of side effects than placebo, while TCAs and SNRIs did (Meister et al., 2016). Study quality was rated low or unclear in most of the trials, and the number of direct comparisons between medicines was relatively small (Meister et al., 2016).
Combining Treatments and Staying Well
A network review pooled 45 drug trials and 15 talking therapy trials (Kriston et al., 2014). Several medicines, including the SSRIs fluoxetine, paroxetine and sertraline, beat placebo, while results for talking therapy were mixed (Kriston et al., 2014). Adding interpersonal psychotherapy to medicine helped more than medicine alone in chronic major depression, but not in dysthymia (Kriston et al., 2014). The evidence on CBASP combined with medicine was partly inconclusive, and several treatments had been tested in single studies (Kriston et al., 2014).
Treatment after improvement is called continuation or maintenance treatment. A Cochrane review of 10 studies with 840 adults pooled 4 studies with 383 people that compared staying on an antidepressant with placebo: about 14% on medicine relapsed compared with about 34% on placebo, on moderate-quality evidence (Machmutow et al., 2019). In studies at low risk of bias alone, that difference was not clear (Machmutow et al., 2019). The authors judged the benefit of medicine uncertain and saw talking therapy as possibly useful (Machmutow et al., 2019).
For adults with depression, NICE says people prescribed an antidepressant should be told they may need to stay on it for at least 6 months after remission, with regular reviews (National Institute for Health and Care Excellence, 2022). NICE also advises tapering antidepressants gradually with the prescriber, and notes that withdrawal symptoms are not a relapse (National Institute for Health and Care Excellence, 2022).
Childhood Adversity and Treatment
Childhood maltreatment means abuse or mistreatment suffered as a child. Across 16 population studies with 23,544 participants, it was linked with more than double the odds of depression that returns or persists (Nanni et al., 2012). In 10 clinical trials with 3,098 participants, people who had been maltreated were less likely to respond or reach remission (Nanni et al., 2012). Neither the age of the samples nor study quality significantly affected these results (Nanni et al., 2012). A Canadian guideline for adults with major depressive disorder also links childhood maltreatment with recurrence (Lam et al., 2024).
What Is Still Uncertain
In medicine trials, some people improve on placebo, and some report side effects on it, which is called a nocebo response. Across 23 antidepressant trials in persistent depressive disorder, the placebo response rate was 31% and the placebo remission rate was 22% (Meister et al., 2017). On placebo, side effects were reported at a rate of 57%, and 4% stopped because of them (Meister et al., 2017). These rates were comparable to those in episodic depression, and placebo response was higher in larger trials (Meister et al., 2017). The authors argue that such factors be taken into account when judging how much a medicine helps (Meister et al., 2017).
One recent review found that several antidepressants, and the antipsychotic amisulpride, did better than placebo in dysthymia (Mathias et al., 2024). Still, the same review called the findings inconclusive, citing few studies and small samples (Mathias et al., 2024). In some of those studies, talking therapy was no better than placebo (Mathias et al., 2024). Several treatments rest on single studies (Kriston et al., 2014), and dysthymia itself can be hard to detect (Schramm et al., 2020).
Learn More
More detail is in the full article on persistent depressive disorder and the guide to depression treatment. There is also a guide to persistent depressive disorder symptoms.
Frequently Asked Questions
What is persistent depressive disorder?
It is a long-lasting depression that includes forms such as dysthymia and chronic major depression (Schramm et al., 2020). One review describes it as often more disabling than episodic depression (Schramm et al., 2020).
Does talking therapy help people with persistent depressive disorder?
A review of 16 trials found that talking therapy helped more than control conditions, though the effect was small (Cuijpers et al., 2010). In dysthymia, medicine did better than talking therapy (Cuijpers et al., 2010).
Do antidepressants work for dysthymia?
A review of 194 trials found that antidepressants worked better than placebo in dysthymia (Levkovitz et al., 2011). Its authors called for longer-term studies (Levkovitz et al., 2011).
Is combining talking therapy and medicine better than either alone?
For CBASP, an analysis of 3 studies found the combination with medicine better on average than either treatment alone (Furukawa et al., 2018). The same analysis found CBASP and medicine about equal on their own (Furukawa et al., 2018).
How long do guidelines advise staying on antidepressants?
NICE in England says people prescribed an antidepressant should be told they may need to stay on it for at least 6 months after remission, with regular reviews (National Institute for Health and Care Excellence, 2022). It also advises tapering them gradually with the prescriber (National Institute for Health and Care Excellence, 2022).
Can a difficult childhood affect how well treatment works?
A review linked childhood maltreatment with depression that persists or returns, and with a lower chance of responding to treatment (Nanni et al., 2012). Anyone with concerns about their treatment can discuss them with a doctor.
How This Article Was Prepared
This is a plain-language patient guide, not a systematic review. Following medical sourcing guidance, it rests on secondary sources rather than single studies: three clinical guidelines and 13 reviews of the research.
- Included: 16 sources, each confirmed against the publisher's or indexer's own record. Five read in full text and 11 from their abstracts. Agency and guideline pages were read on the publisher's own site. Abstracts came from PubMed and Crossref. - Identifiers: 15 references carry a PubMed ID and four a PubMed Central ID, each confirmed by the National Library of Medicine against the cited DOI. - Retractions: 15 sources were checked for retractions and editorial notices; none was retracted. - Publication dates: one from the 2000s, 11 from the 2010s and four from 2020 or later. - Checked against sources: each of the 60 cited sentences was matched to a passage in its source, and an independent reviewer checked the article against those sources over four passes before publication. - Limits: a short guide summarises selected sources and cannot cover every symptom or situation; it is not a diagnosis or a substitute for seeing a health professional. Each sentence was accepted only after its cited source had been searched for contrary evidence.
See our Editorial Policy for the full method.
References
Cuijpers, P., van Straten, A., Schuurmans, J., van Oppen, P., Hollon, S. D., & Andersson, G. (2010). Psychotherapy for chronic major depression and dysthymia: A meta-analysis. Clinical Psychology Review, 30(1), 51-62. https://doi.org/10.1016/j.cpr.2009.09.003 PMID: 19781837
Furukawa, T. A., Efthimiou, O., Weitz, E. S., Cipriani, A., Keller, M. B., Kocsis, J. H., Klein, D. N., Michalak, J., Salanti, G., Cuijpers, P., & Schramm, E. (2018). Cognitive-Behavioral Analysis System of Psychotherapy, drug, or their combination for persistent depressive disorder: Personalizing the treatment choice using individual participant data network metaregression. Psychotherapy and Psychosomatics, 87(3), 140-153. https://doi.org/10.1159/000489227 PMID: 29847831
Imel, Z. E., Malterer, M. B., McKay, K. M., & Wampold, B. E. (2008). A meta-analysis of psychotherapy and medication in unipolar depression and dysthymia. Journal of Affective Disorders, 110(3), 197-206. https://doi.org/10.1016/j.jad.2008.03.018 PMID: 18456340
Jobst, A., Brakemeier, E.-L., Buchheim, A., Caspar, F., Cuijpers, P., Ebmeier, K. P., Falkai, P., Jan van der Gaag, R., Gaebel, W., Herpertz, S., Kurimay, T., Sabaß, L., Schnell, K., Schramm, E., Torrent, C., Wasserman, D., Wiersma, J., & Padberg, F. (2016). European Psychiatric Association Guidance on psychotherapy in chronic depression across Europe. European Psychiatry, 33, 18-36. https://doi.org/10.1016/j.eurpsy.2015.12.003 PMID: 26854984
Kriston, L., von Wolff, A., Westphal, A., Hölzel, L. P., & Härter, M. (2014). Efficacy and acceptability of acute treatments for persistent depressive disorder: A network meta-analysis. Depression and Anxiety, 31(8), 621-630. https://doi.org/10.1002/da.22236 PMID: 24448972
Lam, R. W., Kennedy, S. H., Adams, C., Bahji, A., Beaulieu, S., Bhat, V., Blier, P., Blumberger, D. M., Brietzke, E., Chakrabarty, T., Do, A., Frey, B. N., Giacobbe, P., Gratzer, D., Grigoriadis, S., Habert, J., Husain, M. I., Ismail, Z., McGirr, A., . . . Milev, R. V. (2024). Canadian Network for Mood and Anxiety Treatments (CANMAT) 2023 update on clinical guidelines for management of major depressive disorder in adults. The Canadian Journal of Psychiatry, 69(9), 641-687. https://doi.org/10.1177/07067437241245384 PMID: 38711351 · PMCID: PMC11351064
Levkovitz, Y., Tedeschini, E., & Papakostas, G. I. (2011). Efficacy of antidepressants for dysthymia: A meta-analysis of placebo-controlled randomized trials. Journal of Clinical Psychiatry, 72(4), 509-514. https://doi.org/10.4088/jcp.09m05949blu PMID: 21527126
Machmutow, K., Meister, R., Jansen, A., Kriston, L., Watzke, B., Härter, M. C., & Liebherz, S. (2019). Comparative effectiveness of continuation and maintenance treatments for persistent depressive disorder in adults. Cochrane Database of Systematic Reviews, 2019(5), CD012855. https://doi.org/10.1002/14651858.cd012855.pub2 PMID: 31106850 · PMCID: PMC6526465
Mathias, L., Quagliato, L. A., Carta, M. G., Nardi, A. E., & Cheniaux, E. (2024). Challenges in the treatment of dysthymia: A narrative review. Expert Review of Neurotherapeutics, 24(7), 633-642. https://doi.org/10.1080/14737175.2024.2360671 PMID: 38805342
Meister, R., Jansen, A., Härter, M., Nestoriuc, Y., & Kriston, L. (2017). Placebo and nocebo reactions in randomized trials of pharmacological treatments for persistent depressive disorder: A meta-regression analysis. Journal of Affective Disorders, 215, 288-298. https://doi.org/10.1016/j.jad.2017.03.024 PMID: 28363152
Meister, R., von Wolff, A., Mohr, H., Härter, M., Nestoriuc, Y., Hölzel, L., & Kriston, L. (2016). Comparative safety of pharmacologic treatments for persistent depressive disorder: A systematic review and network meta-analysis. PLoS ONE, 11(5), e0153380. https://doi.org/10.1371/journal.pone.0153380 PMID: 27187783 · PMCID: PMC4871495
Nanni, V., Uher, R., & Danese, A. (2012). Childhood maltreatment predicts unfavorable course of illness and treatment outcome in depression: A meta-analysis. American Journal of Psychiatry, 169(2), 141-151. https://doi.org/10.1176/appi.ajp.2011.11020335 PMID: 22420036
National Institute for Health and Care Excellence. (2022). Depression in adults: Treatment and management (NICE guideline NG222). https://www.nice.org.uk/guidance/ng222/chapter/Recommendations
Negt, P., Brakemeier, E.-L., Michalak, J., Winter, L., Bleich, S., & Kahl, K. G. (2016). The treatment of chronic depression with cognitive behavioral analysis system of psychotherapy: A systematic review and meta-analysis of randomized-controlled clinical trials. Brain and Behavior, 6(8), e00486. https://doi.org/10.1002/brb3.486 PMID: 27247856 · PMCID: PMC4864084
Schramm, E., Klein, D. N., Elsaesser, M., Furukawa, T. A., & Domschke, K. (2020). Review of dysthymia and persistent depressive disorder: History, correlates, and clinical implications. The Lancet Psychiatry, 7(9), 801-812. https://doi.org/10.1016/S2215-0366(20)30099-7 PMID: 32828168
von Wolff, A., Hölzel, L. P., Westphal, A., Härter, M., & Kriston, L. (2013). Selective serotonin reuptake inhibitors and tricyclic antidepressants in the acute treatment of chronic depression and dysthymia: A systematic review and meta-analysis. Journal of Affective Disorders, 144(1-2), 7-15. https://doi.org/10.1016/j.jad.2012.06.007 PMID: 22963896